Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

venues, especially during the first two quarters of 2006, included substantial revenues from the use of the Company's assays in Pfizer's phase III trial of maraviroc.

The net loss was $18.5 million, or $0.14 per common share, in the first nine months of 2007, compared to a net loss of $31.7 million, or $0.24 per common share, for the same period in 2006. Included in these results were substantial non-cash items, which are described below under "Non-GAAP Proforma Results." On a non-GAAP proforma basis, adjusted for these non-cash items, the net loss was $25.6 million, or $0.19 per share, in the first nine months of 2007 compared to a net loss of $15.3 million, or $0.12 per share, in the same period of 2006.

The Company had approximately $30 million in cash resources (comprised of cash, cash equivalents and short-term investments) at September 30, 2007.

Monogram's Trofile Assay and Pfizer's maraviroc

"This has been a pivotal quarter for our HIV business," said William Young, Monogram chief executive officer. "Several positive developments, including FDA approval of Pfizer's maraviroc, culminated in the commercial introduction of Trofile and the rapid establishment of coverage and reimbursement by Medicare. This important reimbursement benchmark bodes well for ongoing discussions with other public and private payers."

Pfizer has announced several positive developments for maraviroc, know as Selzentry(TM) in the U.S. and Celsentri(R), outside of the U.S. These include:

-- positive clinical results from 48 week follow up of patients enrolled

in both the phase III trial of maraviroc in treatment-experienced

patients and the separate trial in treatment-naive patients

-- approval, by both the FDA and the European Commission (EC), of

maraviroc for use in treatment-experienced patients selected by tropism

testing

-- availability, in mid September, of maraviroc throughout the U.S.

Monog
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CLARA, Calif. , July 29, 2014 /PRNewswire-iReach/ ... services agreement with FORMA Therapeutics, Inc., to provide ... and proprietary fragment-based lead discovery platform for novel ... really excited about the opportunity to work with ... fields of epigenetics and protein homeostasis. FORMA Therapeutics, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 July ... vaccine pioneer in the biotechnology industry, announced that ... Coast Securities, Inc. to explore financing opportunities that ... technology, a breakthrough vaccine platform with the potential ... The company exclusively licensed the well-established LAMP platform ...
(Date:7/29/2014)... Quorum Review IRB, the industry ... accreditation by the International Association of Six ... Sigma Deployment Program. The citation recognizes robust organizational ... Quorum’s Lean Six Sigma program was evaluated by ... The designation is a public statement of excellence ...
(Date:7/29/2014)... Boston, MA (PRWEB) July 29, 2014 ... the Library of Congress was recently awarded to Juliana ... in Stoneham, MA, for their project, “From an Egg, ... from among 3,000 final entries for the National History ... more than 300 historians and educators in Washington, D.C. ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... Incorporated (Nasdaq: ARAY ), a global leader in ... results for its second quarter of fiscal 2011, ended December ... closes. A conference call to review the results ... be hosted by Euan S. Thomson, Ph.D., president and chief ...
... Registration is now open for StemCONN 2011. ... in stem cell research, will take place Tuesday, March ... session) and the UConn Health Center (commercial session and ... at http://stemconn.org/ . StemCONN 2011 will ...
... Md., Jan. 13, 2011 Celsion Corporation (Nasdaq: ... to the development and commercialization of innovative oncology drugs, ... securities purchase agreement with a select group of institutional ... to sell 5,000 shares of 8% redeemable convertible preferred ...
Cached Biology Technology:Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 3Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 4
(Date:7/29/2014)... (UM SOD) and Medicine (UM SOM) jointly announced ... million grant award from the National Institute of ... Institutes of Health to study the causes, prevention ... which renews a previous $12 million five-year NIAID-funded ... research by studying chlamydial and gonorrheal diseases as ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by ... its cause remains unknown, a new study by a team ... Bonn in Germany and other European institutions confirms for the ... published on 6 July in Nature Genetics , is ... we swallow, a sphincter in the lower esophagus opens, allowing ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2
... Entomological Society of America (ESA) invites scientists to submit ... which will be held in Knoxville, Tennessee, November 11-14, ... This year,s theme is "A Global Society for ... reflect this theme, if possible. The deadline for ...
... Oilsands development uses a vast amount of water and ... the toxins and metals leftover from extracting and upgrading ... a lightening rod for controversy and a significant risk ... at the University of Calgary and engineers at the ...
... Hay fever (runny nose, sneezing, itchy eyes) is caused by ... These tiny grains bring misery to sufferers through spring and ... weather reports to help sufferers prepare. However new research published ... Allergy shows that, regardless of medication and other allergies, ...
Cached Biology News:Researchers develop new method of cleaning toxins from the oilsands 2Get ready for spring - hay fever worse in spring than summer 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
...
Biology Products: